Analyzing CARA, INSY, and GWPH’s Earnings Trends

Earnings trends

GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017. In the first nine months of 2018, Cara Therapeutics (CARA) and INSYS Therapeutics (INSY) reported a net income of -$53.4 million and -$78.3 million, respectively—compared to -$43.9 million and -$180.1 million, respectively, in the same period the previous year.

In the third quarter, Cara Therapeutics and INSYS Therapeutics reported a net income of -$19.4 million and -$30.6 million, respectively—compared to -$12.4 million and -$166.3 million in the third quarter of 2017.

Analyzing CARA, INSY, and GWPH’s Earnings Trends

EPS trends

GW Pharmaceuticals reported a net EPS of -$10.56 in fiscal 2018. Analysts expect GW Pharmaceuticals’ EPS in 2019 and 2020 to be around -$6.60 and $1.56, respectively.

Cara Therapeutics and INSYS Therapeutics reported an EPS of -$1.54 and -$1.06, respectively, in the first nine months of 2018. Analysts estimate that Cara Therapeutics and INSYS Therapeutics could report an EPS of -$2.16 and -$1.51, respectively, in fiscal 2018.

Analysts’ estimates

Wall Street analysts expect that Cara Therapeutics and INSYS Therapeutics could report a net income of -$22.46 million and $29.21 million, respectively, in the fourth quarter.

In fiscal 2018, analysts expect Cara Therapeutics and INSYS Therapeutics to report a net income of -$76.10 million and -$105.1 million, respectively.

In fiscal 2019 and 2020, analysts expect Cara Therapeutics to report a net income of -$90.94 million and -$99.47 million, respectively. INSYS Therapeutics is expected to report a net income of -$79.87 million and $55.15 million, respectively, in fiscal 2019 and 2020.

In fiscal 2019 and 2020, analysts expect GW Pharmaceuticals to report a net income of -$288.09 million and -$103.23 million, respectively.